BACKGROUND In vivo use of monoclonal antibodies has become routine clinical practice in the treatment of human cancer. CD38 is an attractive target, because it has double roles, as a receptor and an ectoenzyme. Daratumumab, an anti-CD38 antibody, is currently in the clinical trials for multiple myeloma. RESULTS Here we obtained a humanized anti-CD38 antibody, SG003, using SDR-grafting method. SG003 possessed stronger antigen binding activity than Daratumumab, and its epitope was far from that of Daratumumab, an anti-CD38 antibody currently in the clinical trials for multiple myeloma; besides, SG003 showed enhanced antibody-dependent cell-mediated cytotoxicity function and in vivo inhibitory efficacy of tumor growth in xenograft mice model. CONCLUSION SG003 seemed to be a good option to improve the curative effect of CD38-related cancers.

中文翻译：

---

新型抗CD38人源化单克隆抗体SG003通过抗体依赖性细胞介导的细胞毒性作用，较达拉他单抗具有更高的淋巴瘤细胞毒性。

背景技术单克隆抗体的体内使用已成为治疗人类癌症的常规临床实践。CD38作为受体和外部酶具有双重作用，因此是有吸引力的靶标。Daratumumab是一种抗CD38抗体，目前正处于多发性骨髓瘤的临床试验中。结果在这里，我们使用SDR移植方法获得了人源化抗CD38抗体SG003。SG003具有比Daratumumab更强的抗原结合活性，并且其表位与目前在多发性骨髓瘤临床试验中抗CD38抗体Daratumumab的表位相去甚远。此外，SG003在异种移植小鼠模型中显示出增强的抗体依赖性细胞介导的细胞毒性功能和体内肿瘤生长的抑制作用。结论SG003似乎是改善CD38相关癌症疗效的好选择。